Preclinical evaluation of safety of the new hepatoprotector maxar

A. S. Saratikov, N. S. Livshits, F. I. Burchenkova, N. G. Kadychagova, R. R. Akhmedzhanov, L. V. Bashirova

Research output: Contribution to journalArticle

Abstract

The results of preclinical safety evaluation of the new hepatoprotector maxar showed that this drug can be classified as a low-toxicity substance with respect to acute toxicity. No significant functional and structural changes in the systems and organs of experimental animals were observed after a 6-month administration in rats (in a dose of 300, 600, and 1200 mg/kg) and in dogs (500 mg/kg). Maxar exhibited no mutagen and allergen properties, produced no immunotoxicant action, and did not adversely affect the reproduction function.

Original languageEnglish
Pages (from-to)53-55
Number of pages3
JournalEksperimental'naya i Klinicheskaya Farmakologiya
Volume66
Issue number6
Publication statusPublished - 2003

Fingerprint

Animal Structures
Mutagens
Allergens
Reproduction
Toxicity
Dogs
Safety
Pharmaceutical Preparations
Rats
Animals

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Saratikov, A. S., Livshits, N. S., Burchenkova, F. I., Kadychagova, N. G., Akhmedzhanov, R. R., & Bashirova, L. V. (2003). Preclinical evaluation of safety of the new hepatoprotector maxar. Eksperimental'naya i Klinicheskaya Farmakologiya, 66(6), 53-55.

Preclinical evaluation of safety of the new hepatoprotector maxar. / Saratikov, A. S.; Livshits, N. S.; Burchenkova, F. I.; Kadychagova, N. G.; Akhmedzhanov, R. R.; Bashirova, L. V.

In: Eksperimental'naya i Klinicheskaya Farmakologiya, Vol. 66, No. 6, 2003, p. 53-55.

Research output: Contribution to journalArticle

Saratikov, AS, Livshits, NS, Burchenkova, FI, Kadychagova, NG, Akhmedzhanov, RR & Bashirova, LV 2003, 'Preclinical evaluation of safety of the new hepatoprotector maxar', Eksperimental'naya i Klinicheskaya Farmakologiya, vol. 66, no. 6, pp. 53-55.
Saratikov AS, Livshits NS, Burchenkova FI, Kadychagova NG, Akhmedzhanov RR, Bashirova LV. Preclinical evaluation of safety of the new hepatoprotector maxar. Eksperimental'naya i Klinicheskaya Farmakologiya. 2003;66(6):53-55.
Saratikov, A. S. ; Livshits, N. S. ; Burchenkova, F. I. ; Kadychagova, N. G. ; Akhmedzhanov, R. R. ; Bashirova, L. V. / Preclinical evaluation of safety of the new hepatoprotector maxar. In: Eksperimental'naya i Klinicheskaya Farmakologiya. 2003 ; Vol. 66, No. 6. pp. 53-55.
@article{8f9677af1a59499dbffa009243c3ba33,
title = "Preclinical evaluation of safety of the new hepatoprotector maxar",
abstract = "The results of preclinical safety evaluation of the new hepatoprotector maxar showed that this drug can be classified as a low-toxicity substance with respect to acute toxicity. No significant functional and structural changes in the systems and organs of experimental animals were observed after a 6-month administration in rats (in a dose of 300, 600, and 1200 mg/kg) and in dogs (500 mg/kg). Maxar exhibited no mutagen and allergen properties, produced no immunotoxicant action, and did not adversely affect the reproduction function.",
author = "Saratikov, {A. S.} and Livshits, {N. S.} and Burchenkova, {F. I.} and Kadychagova, {N. G.} and Akhmedzhanov, {R. R.} and Bashirova, {L. V.}",
year = "2003",
language = "English",
volume = "66",
pages = "53--55",
journal = "Eksperimental'naya i Klinicheskaya Farmakologiya",
issn = "0869-2092",
publisher = "Izdatelstvo Meditsina",
number = "6",

}

TY - JOUR

T1 - Preclinical evaluation of safety of the new hepatoprotector maxar

AU - Saratikov, A. S.

AU - Livshits, N. S.

AU - Burchenkova, F. I.

AU - Kadychagova, N. G.

AU - Akhmedzhanov, R. R.

AU - Bashirova, L. V.

PY - 2003

Y1 - 2003

N2 - The results of preclinical safety evaluation of the new hepatoprotector maxar showed that this drug can be classified as a low-toxicity substance with respect to acute toxicity. No significant functional and structural changes in the systems and organs of experimental animals were observed after a 6-month administration in rats (in a dose of 300, 600, and 1200 mg/kg) and in dogs (500 mg/kg). Maxar exhibited no mutagen and allergen properties, produced no immunotoxicant action, and did not adversely affect the reproduction function.

AB - The results of preclinical safety evaluation of the new hepatoprotector maxar showed that this drug can be classified as a low-toxicity substance with respect to acute toxicity. No significant functional and structural changes in the systems and organs of experimental animals were observed after a 6-month administration in rats (in a dose of 300, 600, and 1200 mg/kg) and in dogs (500 mg/kg). Maxar exhibited no mutagen and allergen properties, produced no immunotoxicant action, and did not adversely affect the reproduction function.

UR - http://www.scopus.com/inward/record.url?scp=4143141886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4143141886&partnerID=8YFLogxK

M3 - Article

C2 - 14743714

AN - SCOPUS:4143141886

VL - 66

SP - 53

EP - 55

JO - Eksperimental'naya i Klinicheskaya Farmakologiya

JF - Eksperimental'naya i Klinicheskaya Farmakologiya

SN - 0869-2092

IS - 6

ER -